283601-58-1

Docosahexaenoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin (Catalog No. 70665). Arachidonoyl serotonin is a dual antagonist of fatty acid amide hydrolase (FAAH) and the transient receptor potential vanilloid 1 (TRPV1) channel, reducing both acute and chronic peripheral pain. The effects of replacing the arachidonoyl portion with docosahexaenoyl have not been studied.

Docosahexaenoyl serotonin (DHA-5-HT) is an endogenous n-3 fatty acid-serotonin conjugate. Docosahexaenoyl serotonin is an inhibitor of IL-17. Docosahexaenoyl serotonin has anti-inflammatory activity[1][2].

ChEBI: Docosahexaenoyl Serotonin is a fatty amide.

Store at -20°C

[1]. ortar g, cascio mg, de petrocellis l, et al. new n-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. j med chem. 2007 dec 27;50(26):6554-69.
[2]. maione s, de petrocellis l, de novellis v, et al. analgesic actions of n-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid trpv1 receptors. br j pharmacol. 2007 mar;150(6):766-81.